1. Home
  2. SAGE vs GUG Comparison

SAGE vs GUG Comparison

Compare SAGE & GUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAGE
  • GUG
  • Stock Information
  • Founded
  • SAGE 2010
  • GUG 2021
  • Country
  • SAGE United States
  • GUG United States
  • Employees
  • SAGE N/A
  • GUG N/A
  • Industry
  • SAGE Biotechnology: Pharmaceutical Preparations
  • GUG Trusts Except Educational Religious and Charitable
  • Sector
  • SAGE Health Care
  • GUG Finance
  • Exchange
  • SAGE Nasdaq
  • GUG Nasdaq
  • Market Cap
  • SAGE 571.7M
  • GUG 470.0M
  • IPO Year
  • SAGE 2014
  • GUG N/A
  • Fundamental
  • Price
  • SAGE $9.08
  • GUG $15.63
  • Analyst Decision
  • SAGE Hold
  • GUG
  • Analyst Count
  • SAGE 18
  • GUG 0
  • Target Price
  • SAGE $10.06
  • GUG N/A
  • AVG Volume (30 Days)
  • SAGE 2.8M
  • GUG 108.9K
  • Earning Date
  • SAGE 07-30-2025
  • GUG 01-01-0001
  • Dividend Yield
  • SAGE N/A
  • GUG 9.67%
  • EPS Growth
  • SAGE N/A
  • GUG N/A
  • EPS
  • SAGE N/A
  • GUG N/A
  • Revenue
  • SAGE $47,404,000.00
  • GUG N/A
  • Revenue This Year
  • SAGE $102.21
  • GUG N/A
  • Revenue Next Year
  • SAGE $43.01
  • GUG N/A
  • P/E Ratio
  • SAGE N/A
  • GUG N/A
  • Revenue Growth
  • SAGE N/A
  • GUG N/A
  • 52 Week Low
  • SAGE $4.62
  • GUG $12.71
  • 52 Week High
  • SAGE $13.47
  • GUG $15.06
  • Technical
  • Relative Strength Index (RSI)
  • SAGE 71.54
  • GUG 62.89
  • Support Level
  • SAGE $9.04
  • GUG $15.56
  • Resistance Level
  • SAGE $9.30
  • GUG $15.92
  • Average True Range (ATR)
  • SAGE 0.15
  • GUG 0.22
  • MACD
  • SAGE 0.05
  • GUG 0.03
  • Stochastic Oscillator
  • SAGE 91.35
  • GUG 66.85

About SAGE Sage Therapeutics Inc.

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

About GUG Guggenheim Active Allocation Fund of Beneficial Interest

Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.

Share on Social Networks: